Windlas Biotech (NSE:WINDLAS) Research & Development: ₹0 Mil (TTM As of Mar. 2026)


NSE:WINDLAS Windlas Biotech Ltd NSE:WINDLAS
89 GF Score
Price ₹855.75
GF Value ₹936.27
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Windlas Biotech Research & Development?

Windlas Biotech NSE:WINDLAS -0.19% 89 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:WINDLAS with a GF Score™ of 89/100 and a GF Value™ of ₹936.27 (Fairly Valued). The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Windlas Biotech's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Windlas Biotech  (NSE:WINDLAS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Windlas Biotech Research & Development Related Terms

Windlas Biotech Research & Development Historical Data

* Premium members only.

The historical data trend for Windlas Biotech's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windlas Biotech Research & Development Chart

Windlas Biotech Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial 65.11 89.48 78.77 62.51 0.00

Windlas Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:WINDLAS
89GF Score
Windlas Biotech Ltd NSE:WINDLAS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Windlas Biotech Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Windlas Biotech (NSE:WINDLAS) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Windlas Biotech and its competitors.
Is Windlas Biotech's Research & Development too high?
Windlas Biotech's current Research & Development is ₹0 Mil. Overall, Windlas Biotech has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Research & Development compare to ZTS?
Windlas Biotech's Research & Development of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Windlas Biotech and its competitors. Windlas Biotech's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹936.27, compared to a current price of ₹855.75 — trading 8.6% below its estimated fair value. The current Research & Development is ₹0 Mil. Windlas Biotech's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?

Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued. The current stock price of ₹855.75 is trading 8.6% below its estimated GF Value™ of ₹936.27. GuruFocus considers Windlas Biotech to be Fairly Valued.

Key valuation signals for NSE:WINDLAS:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹936.27 vs. price of ₹855.75 (8.6% below fair value)
  • GF Score™: 89/100 with 1 warning sign

No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Windlas Biotech Business Description

Other Exchanges 543329:India
Address Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
89GF Score

Get the complete analysis for NSE:WINDLAS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹855.75
Price
₹936.27
GF Value